Twist Bioscience (TWST) CEO tax-related sale of 2,423 shares disclosed
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported selling 2,423 shares of common stock on 2026-03-06 at an average price of $46.426 per share. After this transaction, she directly holds 860,629 shares.
According to the disclosure, these shares were sold to cover tax withholding obligations triggered by the vesting of restricted stock units, under a mandated "sell to cover" arrangement, rather than as discretionary trades. She also continues to hold employee stock options, including an award exercisable for 64,950 shares of common stock at an exercise price of $67.8500 per share expiring on 2030-08-31.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 2,423 shares ($112,490)
Net Sell
6 txns
Insider
Leproust Emily M.
Role
Chief Executive Officer
Sold
2,423 shs ($112K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 2,423 | $46.426 | $112K |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Common Stock — 860,629 shares (Direct);
Employee Stock Option (right to buy) — 0 shares (Direct)
Footnotes (1)
- Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
FAQ
What did Twist Bioscience (TWST) CEO Emily Leproust report on this Form 4?
Emily M. Leproust reported selling 2,423 shares of Twist Bioscience common stock on March 6, 2026, at an average price of $46.426 per share. Following the transaction, she directly holds 860,629 shares of the company’s common stock.
What stock options does the Twist Bioscience (TWST) CEO continue to hold?
The CEO continues to hold employee stock options, including a grant with an exercise price of $67.8500 per share, expiring August 31, 2030, covering 64,950 underlying shares of Twist Bioscience common stock, in addition to her direct common stock holdings.